R

Royal North Shore Hospital | Renal Medicine - Renal Research Unit

Research site
(Unclaimed)
Location
Level 3, 3E administration, ASB, Sydney, Sydney, Australia
Site insights

Top conditions

Critical Illness (5 trials)

Ischemic Stroke (5 trials)

Carcinoma (4 trials)

Stroke (4 trials)

Cerebral Infarction (3 trials)

Top treatments

gemcitabine
vinorelbine
cisplatin
5-fluorouracil
Cisplatin
Avelumab
67Cu
Dapagliflozin
Levofloxacin
Amoxicillin-clavulanate

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

10 of 72
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)

The purpose of this study is to assess the performance of imaging agent 64Cu-SARTATE in participants with known or suspected Gastroenteropancreatic (...

Enrolling
Neuroendocrine Tumors
Drug: 64Cu-SARTATE

An open-label, ascending dose study for adult patients with Inclusion Body Myositis (IBM).

Active, not recruiting
Inclusion Body Myositis
Drug: ABC008

The primary aim of this clinical study is to assess the safety and clinical performance of the BRight drug-coated balloon (DCB) in the treatment of l...

Active, not recruiting
Peripheral Artery Disease
Device: BRight DCB

Myelodysplastic Syndrome (MDS) is a group of blood disorders where the bone marrow does not produce enough mature red blood cells, white blood cells...

Active, not recruiting
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Drug: CC-486
Drug: Azacitidine

The IMPACT study is a study to test a new experimental drug, IMCY-0098, for the treatment of type 1 diabetes (T1D).In most people with type 1 diabete...

Active, not recruiting
Diabetes Mellitus, Type 1
Drug: Placebo
Drug: IMCY-0098 1350 μg

This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenvatinib (E7080) versus treatment of physician's choice (doxorubicin or p...

Active, not recruiting
Endometrial Neoplasms
Drug: Pembrolizumab
Drug: Doxorubicin

This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant...

Enrolling
Glioma
H3 K27M
Drug: ONC201 + Placebo
Drug: ONC201

OPTIMISTmain is an investigator-initiated and conducted, international, multicentre, stepped wedge cluster randomized controlled trial comparing the...

Enrolling
Acute Ischemic Stroke Patients Receiving Reperfusion Therapy
Other: Low-intensity monitoring strategy
Other: Guideline recommended standard monitoring

The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of SQ3370 in patients with advanced solid tumors.

Enrolling
Cancer
Drug: SQ3370

Rationale:Sodium glucose co transporter 2 (SGLT2) inhibitors are a relatively new class of agents, originally developed as oral antihyperglycemic dru...

Invitation-only
Kidney Failure
Death
Drug: Dapagliflozin 10 mg/day (oral)
Drug: Placebo

Trial sponsors

T

Trans Tasman Radiation Oncology Group (7 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems